BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

May 27, 2021

Announcement no. 12



Managers’ transactions

BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them.

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Thomas Magnussen
2. Reason for the notification  
a) Position/status Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.78, Volume: 60,227
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-25
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Therazone ApS
2. Reason for the notification  
a) Position/status Closely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S



 
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.78, Volume: 191,621
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-25
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Thomas Magnussen
2. Reason for the notification  
a) Position/status Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.52, Volume: 128,344
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-26
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE



1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Therazone ApS
2. Reason for the notification  
a) Position/status Closely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S



 
b) Initial notification/amendment Initial notification
3. Details of the issuer  
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)  
a) Description of the financial instrument, type



of instrument





Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transaction Share sale
c) Price(s) and volume(s) Price: DKK 3.52, Volume: 408,379
d) Aggregated information

  • Aggregated volume

  • Aggregated price
N/A
e) Date of the transaction 2021-05-26
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

For further information, please contact:

Karen Stendal, Legal Counsel

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

 

Attachment



EN
27/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med...

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL 26. september, 2025Meddelelse BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL KØBENHAVN, DANMARK og BOSTON, MA, USA, 26. september – BioPorto A/S (“BioPorto” eller “Selskabet”) (CPH:BIOPOR), annoncerer sin støtte til konferencer med fokus på pædiatriske organtransplantationer og intensiv behandling indenfor nefrologi. Kliniske forskere præsenterer posters, resuméer og nye publikationer, hvor NGAL anven...

 PRESS RELEASE

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL...

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acut...

 PRESS RELEASE

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæ...

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren 11. september, 2025Meddelelse US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. september – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerer det kommende virtuelle arrangement fra US News & World Report: “New Frontiers in Kidney Care”, som vil fokusere på akut og kronisk nyresygdom globalt samt de tiltag, der kan sikre de bedst mulige behandlingsresultater inden for nyresundhed. Webinaret afholdes tors...

 PRESS RELEASE

US News & World Report Webinar “New Frontiers in Kidney Care” features...

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run live on ...

 PRESS RELEASE

Grant of Warrants

Grant of Warrants September 1, 2025 Announcement no. 20                                                                          Grant of Warrants Copenhagen, Denmark, September 1, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 5,000,000 warrants to a member of the Executive Management. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.28 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch